# US 10,117,915 B2 · Modulation of yeast-based immunotherapy products and responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,915 B2
- Document ID: US10117915B2
- Status: Granted
- Kind: B2
- Application number: 14/536,903
- Filed: 2014-11-10
- Published: 2015-07-16
- Granted: 2018-11-06
- Earliest claimed: 2009-09-14
- Assignees: The Regents of the University of Colorado, a body corporate
- Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate
- Inventors: Donald Bellgrau; Beth Tamburini
- Web page: https://patentgrep.com/patent/US10117915B2

## CPC

- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 36/06: Fungi, e.g. yeasts
- A61K 36/064: Saccharomycetales, e.g. baker's yeast
- A61K 39/39541: {against normal tissues, cells}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/5023: {on expression patterns}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions.

## Claims

### Claim 1

A method to inhibit the production or survival of CD4+ TH17 cells in a subject, comprising administering to a subject:
a) a yeast-based immunotherapy composition comprising a whole yeast and an antigen; and
b) an agent that inhibits the production or survival of CD4+ TH17 cells, wherein the agent inhibits interleukin-17 (IL-17), and is an anti-IL-17A antibody;
wherein the administration of the agent is prior to, in conjunction with, and/or following administration of the yeast-based immunotherapy composition, and wherein the production or survival of CD4+ TH17 cells is inhibited in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein T cells isolated from the subject do not proliferate or proliferate weakly in response to contact with a yeast-based immunotherapy composition.

### Claim 3 (depends on 1)

The method of claim 1, wherein T cells isolated from the subject have greater than normal retinoid-related orphan receptor (ROR)-γ expression and/or have greater than normal levels of IL-17 production.

### Claim 4 (depends on 1)

The method of claim 1, wherein the yeast-based immunotherapy composition is administered in one or more doses over a period of time prior to commencing the administration of the agent.

### Claim 5 (depends on 1)

The method of claim 1, wherein the yeast used to produce the yeast-based immunotherapy composition have been engineered to carry or express the agent.

### Claim 6 (depends on 1)

The method of claim 1, wherein administration of the agent and the yeast-based immunotherapy enhances CD8+ T cell responses, as compared to administration of the yeast-based immunotherapy composition alone.

### Claim 7 (depends on 1)

The method of claim 1, wherein the whole yeast is a heat-inactivated whole yeast.

### Claim 8 (depends on 1)

The method of claim 1, wherein the whole yeast is from Saccharomyces.

### Claim 9 (depends on 1)

The method of claim 1, wherein the whole yeast is from Saccharomyces cerevisiae.